Shares of Microbot Medical Inc. (NASDAQ:MBOT) traded up 6% during trading on Wednesday . The stock traded as high as $1.08 and last traded at $1.06. 1,313,456 shares changed hands during mid-day trading, an increase of 39% from the average session volume of 946,433 shares. The stock had previously closed at $1.00.

Separately, ValuEngine raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd.

The firm’s 50-day moving average is $1.14 and its 200-day moving average is $3.35. The firm’s market cap is $44.92 million.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.44. Equities research analysts forecast that Microbot Medical Inc. will post ($25.02) earnings per share for the current fiscal year.

In other news, Director Yoseph Bornstein sold 45,610 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $1.01, for a total transaction of $46,066.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Leon Lewkowicz sold 71,224 shares of the firm’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $1.67, for a total transaction of $118,944.08. Following the transaction, the insider now directly owns 3,078,214 shares of the company’s stock, valued at $5,140,617.38. The disclosure for this sale can be found here. 31.83% of the stock is owned by corporate insiders.

An institutional investor recently raised its position in Microbot Medical stock. Bank of Montreal Can increased its position in shares of Microbot Medical Inc. (NASDAQ:MBOT) by 90,909.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,022 shares of the biotechnology company’s stock after purchasing an additional 20,000 shares during the quarter. Bank of Montreal Can owned approximately 0.07% of Microbot Medical worth $116,000 at the end of the most recent quarter. Institutional investors and hedge funds own 4.72% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/08/microbot-medical-inc-mbot-trading-6-higher.html.

Microbot Medical Company Profile

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.